Sitagliptin in Recurrent/Progressive Grade 4 Glioma

Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.

Trial Details

NCT ID
NCT07541781
Phase
PHASE1
Sponsor
Kailin Yang, MD, PhD
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Interventions
  • Sitagliptin
  • Bevacizumab
Locations (sample)
  • Iowa City, Iowa, United States|41.66113,-91.53017

Key Eligibility Criteria

  • Subjects must have histologically or cytologically confirmed WHO grade 4 glioma for which disease recurrence/progression after first line therapy i…
  • Subjects must not have received sitagliptin or bevacizumab for this disease.
  • Age \>18 years
  • Performance status: ECOG performance status 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →